Terminated trial tests Last-Chance drugs for tough kidney cancers
NCT ID NCT05935748
Summary
This study tested two different drug combinations for people with advanced kidney cancer that had stopped responding to standard treatments. The trial aimed to find safe doses and see if these combinations could shrink tumors or slow disease progression. The study was terminated early after enrolling only 18 participants, so results are limited.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065-6094, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390-9324, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Michigan-Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.